Table 1.

Rituximab in idiopathic membranous nephropathy

Reference	Study	Dose of rituximab	Patients, N	Outcome
Fiorentino et al24	Prospective observational study	375 mg/m2, 4‐weekly IV infusions	38	39.5% CR
				36.8% PR
				76.3% CR or PR
				Decreased proteinuria
				Increased albuminemia
				Decrease in circulating CD19+ B‐cells
Ruggenenti et al55	Prospective observational study	375 mg/m2, 4 weekly IV infusions	8	Decreased proteinuria
				Increased serum albumin concentration
				Renal function stabilized
Fernando et al56	Prospective study	375 mg/m2, 4 weekly IV infusions	20	Decreased proteinuria
				Increased creatinine clearance
				CR in 4 patients
				PR in 12 patients
Busch et al57	Prospective single center study	375 mg/m2, 4 weekly IV infusions	14	Decreased proteinuria
				CR in 3 patients
				PR in 12 patients
Ruggenenti et al58	Prospective observational study	375 mg/m2, 4 weekly IV infusions	100	65 patients achieved CR or PR
				Increased serum albumin
				Decreased proteinuria
Cravedi et al59	Prospective, matched‐cohort study	375 mg/m2, 4 weekly IV infusions	11	Decreased proteinuria
				8 patients and 7 reference patients achieved full (3 vs 2) or partial (5 per cohort) proteinuria remission

CR, complete remission; PR, partial remission.